EUVIMEDEUVIMED entdecken
Fallbericht

PTEN and PIK3CA Mutation Positive Breast Neuroendocrine Carcinoma Treated with Molecularly Targeted Therapy Including Capivasertib

Kyoko Shimoyama, Yoshihiro Ikura

The Tohoku Journal of Experimental Medicine · 2026 · 270 (1) · 181-186

DOI: 10.1620/tjem.2026.j019 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Tohoku Journal of Experimental Medicine, 2026. Verfasst von Kyoko Shimoyama und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Takatsuki General Hospital. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Mutation, Breast Neoplasms, Carcinoma, Neuroendocrine. Die Arbeit nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast neuroendocrine carcinoma (BNEC) is rare (< 0.1%) but is clinically important due to its rapidly progression, treatment-resistant, and poor prognosis despite being hormone receptors-positive. No effective treatment for BNEC has been established. BNEC is little recognized, so it may be overlooked as an invasive carcinoma of no special type. However, an early diagnosis of BNEC is critical, as it allows for comprehensive genomic profiling (CGP). We present a case of a woman in her 40s with heterochronic bilateral breast cancer, who was ultimately diagnosed with BNEC due to the rapid disease progression with bone, liver, and lung metastases, during semiannual follow-up. CGP revealed PTEN, PIK3CA, and ESR1 mutations as well as a high tumor mutational burden (TMB-high). While she received everolimus, abemaciclib, and bevacizumab, capivasertib was most effective. BNEC is rare, but an early diagnosis, based on clinical course, is key for CGP and correct treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Class I Phosphatidylinositol 3-KinasesMutationBreast NeoplasmsCarcinoma, NeuroendocrinePTEN PhosphohydrolaseMolecular Targeted TherapyPyrimidinesPyrrolesHumansFemale

Stichwörter der Autor:innen

PIK3CA mutationbreast neuroendocrine carcinomacapivasertibmetastatic breast cancermolecularly targeted therapy

Substanzen

Class I Phosphatidylinositol 3-KinasesPIK3CA protein, humanPTEN PhosphohydrolasePTEN protein, humanPyrimidinesPyrroles

Autor:innen und Institutionen

  • Department of Breast Surgery, Takatsuki General Hospital.
  • Department of Pathology, Takatsuki General Hospital.

Zitieren

APA

Shimoyama, K., & Ikura, Y. (2026). PTEN and PIK3CA Mutation Positive Breast Neuroendocrine Carcinoma Treated with Molecularly Targeted Therapy Including Capivasertib. The Tohoku Journal of Experimental Medicine, 270(1), 181-186. https://doi.org/10.1620/tjem.2026.j019

Vancouver

Shimoyama K, Ikura Y. PTEN and PIK3CA Mutation Positive Breast Neuroendocrine Carcinoma Treated with Molecularly Targeted Therapy Including Capivasertib. The Tohoku Journal of Experimental Medicine. 2026;270(1):181-186. doi:10.1620/tjem.2026.j019

BibTeX
@article{Shimoyama2026,
  author = {Shimoyama, Kyoko and Ikura, Yoshihiro},
  title = {PTEN and PIK3CA Mutation Positive Breast Neuroendocrine Carcinoma Treated with Molecularly Targeted Therapy Including Capivasertib},
  journal = {The Tohoku Journal of Experimental Medicine},
  year = {2026},
  volume = {270},
  number = {1},
  pages = {181--186},
  doi = {10.1620/tjem.2026.j019}
}
Kostenlos starten →